Abstract
Since 2002, an MS Registry has been implemented by the German MS Society in more than 100 German MS centres. The objective is to provide information about disease characteristics, and to monitor the health care situation in a large population of patients. The aim of this report is to give detailed results on MS symptoms. By October 2008, data sets from 16,554 patients were recorded by 86 centres. A strikingly high number of persons suffered from fatigue and other “invisible” symptoms during early and late stages of the disease, underscoring the negative impact of these symptoms on quality of life in MS patients.
This is a preview of subscription content, log in via an institution to check access.
References
Flachenecker P, Stuke K (2008) National MS registries. J Neurol 255(Suppl 6):102–108
Flachenecker P, Stuke K, Elias W, Freidel M, Haas J, Pitschnau-Michel D, Schimrigk S, Zettl UK, Rieckmann P (2008) Multiple-Sklerose-Register in Deutschland. Ausweitung des Projektes 2005/2006. Dtsch Ärztebl 105:113–119
Flachenecker P, Zettl UK, Götze U, Haas J, Schimrigk S, Elias W, Pette M, Eulitz M, Hennig M, Bertram J, Hollweck R, Neiss A, Daumer M, Pitschnau-Michel D, Rieckmann P (2005) MS Register in Deutschland—Design und erste Ergebnisse der Pilotphase. Nervenarzt 76:967–975
Flachenecker P, Zettl UK, Götze U, Stuke K, Elias W, Eulitz M, Haas J, Pette M, Pitschnau-Michel D, Schimrigk S, Rieckmann P (2007) MS-Register in Deutschland: abschliessende Ergebnisse der Pilotphase. Neurol Rehabil 13:193–200
Lo AC, Hadjimichael O, Vollmer TL (2005) Treatment patterns of multiple sclerosis patients: a comparison of veterans and non-veterans using the NARCOMS registry. Mult Scler 11:33–40
Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis. Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:907–911
Multiple Sklerose Therapie Konsensus Gruppe (2008) Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol 255:1449–1463
Pittock SJ, Mayr WT, McClelland RL, Jorgensen NW, Weigand SD, Noseworthy JH, Weinshenker BG, Rodriguez M (2004) Change in MS-related disability in a population-based cohort: a 10-year follow-up study. Neurology 62:51–59
Rodriguez M, Siva A, Ward J, Stolp Smith K, O’Brien P, Kurland L (1994) Impairment, disability, and handicap in multiple sclerosis: a population-based study in Olmsted County, Minnesota. Neurology 44:28–33
Weinshenker BG, Bass B, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC (1989) The natural history of multiple sclerosis: a geographically based study. 1. Clinical course and disability. Brain 112:133–146
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stuke, K., Flachenecker, P., Zettl, U.K. et al. Symptomatology of MS: results from the German MS Registry. J Neurol 256, 1932–1935 (2009). https://doi.org/10.1007/s00415-009-5257-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-009-5257-5